INDVIndivior Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Indivior Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDV본 종목 | $4.9B#1 | 20.5x#1 | — | 3.9x#1 | 4.3%#1 | 2900.0%#1 | 21.1%#1 | — | 137.8%#1 | 4#1 | 98.4%#1 | — |
| HYFT | $60M#5 | — | — | — | — | — | — | — | — | — | — | — |
| IMMP | $566M#3 | — | — | — | — | — | — | — | — | — | — | — |
| IMRN | $260M#4 | — | — | — | — | — | — | — | — | — | — | — |
| IMRX | — | — | — | — | -100.0%#3 | 8.2%#3 | — | -27.1%#1 | — | — | — | — |
| INCR | $53M#6 | — | — | — | — | — | — | — | — | — | — | — |
| INTI | — | — | — | — | — | 1.2%#4 | — | — | — | — | — | — |
| IOBTQ | — | — | — | — | — | -10.9%#5 | — | -10483.0%#2 | — | — | — | — |
| ISCO | — | — | — | — | 0.2%#2 | -100.0%#6 | -2.9%#2 | — | — | — | — | — |
| ITRMF | — | — | — | — | — | 35.4%#2 | — | — | — | — | — | — |
| IVA | $867M#2 | — | — | — | — | — | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice